Third, with time and increasing knowledge of bronchiectasis, changes may occur in the clinical interpretation of this disease and the relative impact of each symptom on the patient. 13 In short, it is ...

The Food and Drug Administration (FDA) has approved Brinsupri ™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older.